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Abstract
Background: Introduction of the 7-valent pneumococcal conjugate vaccine (7vCRM) in several countries has led to
a rapid, significant drop in vaccine-type invasive pneumococcal disease (IPD) in immunized children. In the United
States and some other countries with high antibiotic use, a subsequent rise in serotype 19A IPD has been taken to
indicate that the 19F conjugate in the vaccine provides no cross-protection against the immunologically related
19A.
Discussion: We systematically assessed the clinical efficacy and effectiveness of 19F-containing vaccines against
19A disease or nasopharyngeal carriage by searching English-language articles in the electronic databases PubMed,
Current contents, Scopus, and Embase from 1985 to 2008. The vaccine efficacy and effectiveness point estimates
were consistently positive for modest protection against 19A IPD and acute otitis media (AOM). However, statistical
significance was not reached in any individual study. No consistent impact of 7vCRM on 19A nasopharyngeal
colonization could be detected. These findings are discussed in context of immunogenicity analyses indicating that
7vCRM induces functionally active anti-19A antibodies after the booster dose, and that other 19F-containing
vaccine formulations may elicit higher levels of such antibodies after both primary and booster doses.
Summary: Taken together, these results suggest that 19F-conjugates can provide some protection against 19A
disease. The magnitude of this protection in a given setting will likely depend on several factors. These include the
anti-19A immunogenicity of the specific vaccine formulation, the number of doses of that formulation needed to
elicit the response, and the burden of 19A disease that occurs after those doses. It is possible that a modest
protective effect may be obscured by the presence of countervailing selection pressures (such as high antibiotic
use) that favor an increase in colonization with antibiotic-non-susceptible strains of 19A.
Background
Since the 7-valent pneumococcal conjugate vaccine
(7vCRM; Prevenar™/Prevnar™; Wyeth Vaccines) was first
introduced in the United States (US) in 2000, invasive
pneumococcal disease (IPD) due to Streptococcus pneu-
moniae vaccine-serotypes (4, 6B, 9V, 14, 18C, 19F, and
23F) has dramatically decreased among children and
adults [1-6].
Serotypes 6A and 19A were not included in 7vCRM
and several other pneumococcal conjugate vaccines
(PCVs) because it was anticipated that the immunologi-
cal similarities of vaccine serotypes 6B and 19F, respec-
tively, might elicit sufficient cross-protection [7]. There
is now convincing evidence that the 6B conjugate con-
tained in 7vCRM (in which the 6B polysaccharide is
conjugated to a non-toxic variant of diphtheria toxin)
provides a high degree of cross-protection against 6A
IPD [8,9], acute otitis media (AOM) [10], and even
offers a significant level of herd protection [8]. An effi-
cacy trial with the 11Pn-PD vaccine candidate (in which
6B was conjugated to the non-typeable Haemophilus
influenzae protein D) also suggested cross-protection
against 6A AOM [11].
For serotype 19A, some preclinical studies support the
possibility of cross-protection. For instance, serum from
infants immunized with a 19F tetanus toxoid conjugate
provided protection against lung infection caused by
both 19F and 19A in a murine model [12]. Nonetheless,
clear clinical evidence of cross-protection against 19A
disease by 19F-containing PCVs has been lacking.
Indeed, the rise in 19A IPD in certain populations well
immunized with 7vCRM would seem to argue against it * Correspondence: william.p.hausdorff@gskbio.com
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reproduction in any medium, provided the original work is properly cited.[1-6]. In the US, for example, the incidence of 19A IPD
rose in children >5 from approximately 2.5 cases/
100,000 in 1998-9 (prior to 7vCRM) to 9 cases/100,000
in 2005 [5].
However, analysis of clinical and post-licensure studies
with 7vCRM and other pneumococcal conjugate vac-
c i n e ss u g g e s t sam o r ec o m p l e xs i t u a t i o n .T h i sr e v i e w
discusses the literature on cross-protection against 19A
disease and colonization provided by 19F-containing
vaccines, and relates these results to recently published
immunogenicity data.
Discussion
Clinical efficacy and effectiveness data
Table 1 presents a review of prospective and retrospec-
tive clinical studies and post-licensure surveillance stu-
dies with 7vCRM and other 19F-containing vaccines.
We wish to highlight two findings. First, in every analy-
sis with 5 or more 19A cases (Figure 1), the anti-19A
point estimate is positive, with values ranging from 13%
to 67%. This suggests that the true efficacy or effective-
ness is probably not null. Secondly, however, none of
the anti-19A efficacy or effectiveness point estimates is,
by itself, statistically significant.
There is considerable variability in the point estimates
in Table 1, which could conceivably be related to the
different numbers of vaccine doses received by children
in each study. There is support for this concept for 6B
and 6A. Dagan et al., showed that whereas three primary
doses (at 2,4, and 6 months of age) of 7vCRM signifi-
cantly decreased both 6B and 6A nasopharyngeal coloni-
zation as measured in the 2
nd year of life, two primary
doses alone (4 and 6 months) decreased 6B but not 6A
colonization [13].
Two of the studies in Table 1 may provide some
insight here. First, the analysis with the lowest point
estimate for 19A cross-protection (13% [95% confidence
intervals, -79% to 58%]) is a weighted meta-analysis [14]
of four randomized, double-blind, placebo-controlled,
efficacy studies using 7vCRM [15,16] or the related
9vCRM vaccine [17,18]. Twenty six of the 28 19A cases
included in this analysis were contributed by the two
9vCRM studies conducted in Africa in which no booster
dose was given.
Also potentially supporting the importance of a boos-
ter dose is the heterogeneous post-marketing experience
with 19A in the US. The original report on the impact
of 7vCRM introduction in the US pointed to a 40% (p =
0.09) decrease in the incidence of serotype 19A IPD in
children younger than 2 years of age between the pre-
7vCRM years 1998-1999 and the first full post-7vCRM
year 2001 [19]. This decrease contrasts with the rise in
19A disease detected starting in 2002 in the same active
surveillance system [3] and which continued for several
years [5]. The onset of the rise coincided with the severe
shortage of 7vCRM in the US between 2001 and 2004
that resulted in many children receiving fewer than
three primary doses and/or no booster dose [20].
In contrast to the IPD and AOM data summarized in
Table 1, there does not appear to be evidence of a con-
sistent 7vCRM effect on 19A colonization itself (Table
2), even among different analyses within the same vac-
cine study population [21-23]. In fact, in some 7vCRM
carriage studies at certain ages or time points, an
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Figure 1 Vaccine efficacy or effectiveness of 19F-containing vaccines against 19A disease. Depicted are point estimates with 95%
confidence intervals from individual studies or metanalyses with at least five 19A cases. PS14-V, 14 valent polysaccharide vaccine; 7vCRM, 7-
valent conjugate vaccine with crm197 carrier; 9vCRM, 9-valent conjugate vaccine candidate with crm197 carrier; 7vOMP, 7-valent conjugate
vaccine candidate with outer membrane protein carrier; IPD, invasive pneumococcal disease; AOM, acute otitis media. See Table 1 for more study
details.
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Page 2 of 7Table 1 Studies examining efficacy or effectiveness of 19F-containing vaccines against 19A IPD and AOM
Study or
Analysis
Vaccine Vaccine
regimen
Endpoint Age
group
Total
Number
of
Subjects
Numbers
of 19F
Cases
% VE against 19F
(95% CI)
Numbers
of 19A
Cases
% VE against
19A
(95% CI)
Polysaccharide vaccine IPD
US indirect
cohort analysis
[37]
PS14-V* 1 dose as per
US recomm.
IPD > 5 y 2837 total
cases
12 (vacc)
32(unvacc)
11
(-86,,56)
10 (vacc)
42(unvacc)
44
(-21, 74)
Conjugate vaccines IPD
N. California
Kaiser
Permanente
efficacy [15,38]
a
7vCRM 2,4,6,12-15 mo IPD after
≥ 3
doses
2m o
to ~3.5
y
18927
(vacc)
18941
(ctrl)
2 (vacc)
13 (ctrl)
85
(32, 97)
0 (vacc)
1 (ctrl)
67
(-719, 99)
Native Americans
efficacy [16,38]
a
7vCRM 2,4,6,12-15 mo IPD after
≥ 3
doses
2m o
to 2 y
7532
(vacc)
7151 (ctrl)
0 (vacc)
1 (ctrl)
68
(-677, 99)
1 (vacc)
0(ctrl)
-185
(-900, 88)
South African
HIV- efficacy
[17,38]
a
9vCRM 6, 10, 14 wks IPD after
3 doses
6w k
to 6.2
y
18633
(vacc)
18626
(ctrl)
0 (vacc)
1 (ctrl)
67
(-718, 99)
3 (vacc) 1
(ctrl)
-200
(-900, 69)
South African HIV
+ efficacy [17,38]
a
9vCRM 6, 10, 14 wks IPD after
3 doses
6w k
to 6.2
y
1289
(vacc)
1288 (ctrl)
5 (vacc)
3 (ctrl)
-67
(-595,60)
3 (vacc)
6 (ctrl)
50
(-99, 88)
Gambia efficacy
[14,39]
a
9vCRM 6, 10, 14 wks IPD after
3 doses
6w k
to 2.9
y
8718
(vacc)
8719 (ctrl)
0 (vacc)
2 (ctrl)
80
(-317, 99)
6 (vacc)
7 (ctrl)
14
(-155, 71)
Meta-analysis of
preceding efficacy
studies(
a)
7vCRM
&
9vCRM
see individual studies 55099
(vacc)
54725
(ctrl)
7 (vacc)
20 (ctrl)
61
(13, 82)
13 (vacc)
15 (ctrl)
13
(-79, 58)
US post-
marketing
surveillance [19]
7vCRM 2,4,6,12-15 mo;
catch-up
schedule for < 2
y
IPD (2
nd
yr after
launch)
>2y
(not all
vacc)
~433,000 79 (pre)
14 (post)
83
(72, 90)
(% decrease decrease
in estimated rate
from pre-7vCRM)
20 (pre)
12 (post)
40
(-5, 68)
(% decrease in
estimated rate
from pre-7vCRM)
US CDC case-
control [9]
7vCRM 2,4,6,12-15 mo IPD ≥ 1
dose
3t o5 9
mo
n.a. 34
discordant
sets
87
(65, 95)
46
discordant
sets
26
(-45, 62)
Canada (Québec)
[40]: case-control
7vCRM 2,4,12 mo IPD ≥ 1
dose
<5 y n.a. 3 (vacc); 8
(unvacc)
93 (61,99) 29 (vacc);
8 (unvacc)
42
(-76, 79)
Conjugate Vaccines AOM
Finland [10]:
efficacy (FinOM)
7vCRM 2,4,6,12 mo AOM
after ≥ 3
doses
6.5 to
24 mo
831 (vacc)
831 (ctrl)
43 (vacc)
58 (ctrl)
25
(-14, 51)
17 (vacc)
26 (ctrl)
34
(-26, 65)
Finland [41]:
efficacy(FinOM)
7vOMP 2,4,6,12 mo AOM
after ≥ 3
doses
6.5 to
24 mo
831 (vacc)
831 (ctrl)
37 (vacc)
58 (ctrl)
37
(1, 59)
22 (vacc)
26 (ctrl)
16
(-53, 54)
Czech/Slovak [11]:
efficacy (POET)
11Pn-
PD
3,4,5,12-15 mo AOM
after ≥ 3
doses
5t o2 7
mo
2489
(vacc)
2479 (ctrl)
24 (vacc)
43 (ctrl)
44
(8, 66)
1 (vacc)
3 (ctrl)
67
(-209, 97)
*PS14-V, 14 valent polysaccharide vaccine, contained 19F but not 19A; it was replaced in the early 1980s by the 23-valent vaccine containing both 19A and 19F
serotypes.
aEach of the 5 analyses (from 4 separate studies) is also included in the metanalysis in italics. Mo, month; n.a., not available; VE, vaccine efficacy/
effectiveness; wk, week; y, year; vacc, active vaccine group; unvacc, unvaccinated; ctrl, control; 7vCRM, 7-valent conjugate vaccine with CRM197 carrier; 9vCRM, 9-
valent conjugate vaccine candidate with CRM197 carrier; 7vOMP, 7-valent conjugate vaccine candidate with outer membrane protein carrier; IPD, invasive
pneumococcal disease; AOM, acute otitis media
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Page 3 of 7apparent increase in 19A carriage is observed (odds
ratios greater than 1 or negative point estimates for effi-
cacy) following vaccination, although these changes
were generally not statistically significant [22]. This sug-
gests that any effect of 7vCRM on 19A may be limited
to prevention of disease once colonized, but not on pre-
venting 19A colonization in the first place.
Immunogenicity data
The ability of pneumococcal vaccines to induce func-
tional anti-capsular polysaccharide antibodies is consid-
ered to be the major mechanism by which these
vaccines prevent IPD [24,25]. Vaccine-induced antibody
levels measured by ELISA [25] and especially by opso-
nophagocytic activity assays (OPA) against individual
pneumococcal serotypes have been shown to correlate
well with clinical effectiveness [26]. Henckaerts et al.
[24] showed that, following three primary doses of
7vCRM, virtually no child (3%) developed anti-19A OPA
above the threshold suggested to correlate with clinical
effectiveness against IPD (i.e., OPA titer ≥8) [25,26].
More recent studies from three different laboratories are
consistent with these findings [27-29]. In contrast, a
booster dose, of 7vCRM elicited some anti-19A OPA
activity, with approximately 25%-30% of children having
OPA titers ≥8 [29,30].
Other pneumococcal conjugate vaccines with distinct
chemistries and carriers may have different immunologi-
cal properties. For example, it has been observed that
the periodate oxidation step used to link the 19F
Table 2 Studies examining efficacy or effectiveness of 19F-containing vaccines against 19A carriage
Study &
location
Vaccine Vaccine
regimen
Age group(s)
sampled
Number
of
Subjects
Number
of 19F
isolates
Efficacy against 19F
VE or OR
(95% CI or p value)
Number
of 19A
isolates
Efficacy against
19A
VE or OR
(95% CI or p
value)
South Africa [42]:
double blind,
randomized,
efficacy
9vCRM 6,10,14 wk 9 mo 242 (vacc)
239 (ctrl)
19 (vacc)
32 (ctrl)
VE 42%* (p = 0.05) 7 (vacc)
11 (ctrl)
VE 37%* (NS)
Israel [43]: double
blind,
randomized
efficacy
9vCRM 12-24 mo
received 2
doses; ≥ 24
mo 1 dose
15-35 mo 36-≥
48 mo
816 (vacc)
790 (ctrl)
1071
(vacc)
1073 (ctrl)
41 (vacc)
62 (ctrl)
57 (vacc)
52 (ctrl)
OR 0.58 (p = 0.08)
OR 1.11 (p = 0.69)
n.a. = 113
total (all
groups
combined)
OR 0.60** (p = 0.38)
OR 1.25** (p = 0.56)
US Navajo
Apache [21]:
double blind,
randomized
efficacy
7vCRM 2,4,6,12-15 mo
(87%)
1-7 y (median
3.3y)
All >12 mo
since last dose
468 (vacc)
281 (ctrl)
24 (vacc)
16 (ctrl)
OR 0.89 (0.47-1.72) 12 (vacc)
10 (ctrl)
OR 0.71 (0.30-1.67)
US Navajo
Apache [23]:
double blind,
randomized
efficacy
7vCRM 2,4,6,12-15 mo 7 mo 227 (vacc)
226 (ctrl)
2 (vacc)
11 (ctrl)
OR not calculated
because “small sample
size resulted in non-
convergence of model”
10 (vacc)
4 (ctrl)
OR 1.75 (0.41-7.58)
12 mo 226 (vacc)
208 (ctrl)
7 (vacc)
8 (ctrl)
3 (vacc)
7 (ctrl)
OR 0.38 (0.09-1.57)
18 mo 239 (vacc)
219 (ctrl)
18 (vacc)
8 (ctrl)
14 (vacc)
10 (ctrl)
OR 1.68 (0.7-4.05)
US Navajo
Apache [22]:
double blind,
randomized
efficacy
7vCRM Infants: 2,4,6,
12-15 mo; 12-
23 mo: 2
doses
Unvaccinated
children/adults
in study
households
2048
(vacc)
1376 (ctrl)
29 (vacc)
37 (ctrl)
OR 0.52 (0.31-0.87) 15 (vacc)
23 (ctrl)
OR 0.34 (0.16-0.75)
France [44]:
effectiveness
7vCRM ≥ 1 dose Children w/
AOM 6-24 mo
(mean 14 mo)
575 (vacc)
1331 (ctrl)
59 (vacc)
178 (ctrl)
24%* (p = 0.06) 50 (vacc)
92 (ctrl)
-26%* (p = 0.2)
Greece [45]:
effectiveness
7vCRM 12-23 mo: 2
doses (13%); ≥
24 mo: 1 dose
(85%)
13-76 mo
(median 47
mo)
285 (vacc)
582 (ctrl)
24 (vacc)
64 (ctrl)
36%* 3 (vacc)
14 (ctrl)
58%*
*Only case numbers provided in original paper; approximate % VE calculated for this table;
**confidence intervals for odds rations not provided in original publication.
Mo, month; NS; not significant; OR, odds ratio; VE, vaccine efficacy/effectiveness; wk, week; y, year. 7vCRM, 7-valent conjugate vaccine with CRM197 carrier.
9vCRM; 9-valent conjugate vaccine candidate with CRM197 carrier.
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Page 4 of 7polysaccharide to the CRM197 carrier protein in 7vCRM
prior to reductive amination alters the antigenicity of
the polysaccharide [31]. In three separate studies
[29,30,32], 20%-30% of children receiving a 3-dose pri-
mary series of PHiD-CV (a recently licensed 10-valent
pneumococcal non-typeable H. influenzae protein Dcon-
jugate vaccine in which 19F is conjugated to diphtheria
toxoid; Synflorix™, GlaxoSmithKline Biologicals) had 19A
OPA titers ≥8, compared with fewer than 5% of
7vCRM-immunized children in the same studies.
Furthermore, a booster dose in the second year of life
led to 19A OPA titers above this level in approximately
50% of PHiD-CV-immunized children and 30% of
7vCRM-immunized children [29,30].
Differences in OPA levels may reflect variability not
only in the quantity, but also in the quality of the antibo-
dies elicited by different conjugates. Nurkka et al. studied
the functionality of cross-reactive antibodies induced by
7vCRM, 7vOMPC (polysaccharides conjugated to outer
membrane proteins from Neisseria meningitidis, Merck
Sharpe & Dohme), and 11Pn-PD, each with 19F conju-
gated to different carrier proteins [33]. In serum samples
selected to have similar antibody concentrations as mea-
sured by ELISA, the 19A OPA titers were higher in the
11Pn-PD group than in the two other groups [33].
Conclusion
The clinical efficacy, effectiveness, and immunogenicity
studies summarized here suggest that immunization
with 19F-containing pneumococcal conjugate vaccines
can provide some direct protection against 19A disease.
Nonetheless, the limited anti-19A activity of 7vCRM in
particular, which appears insufficient to prevent 19A
colonization, was evidently also insufficient to prevent
or reverse [5] a net rise in 19A disease in young chil-
dren in countries where high antimicrobial use has led
to greatly increased colonization by antibiotic non-sus-
ceptible strains, including certain clones of 19A
[5,34-36]. This does not exclude the possibility, however,
that the modest effect of 7vCRM on disease may have
attenuated or slowed down the rise. In any case, a pro-
tective effect of 7vCRM against 19A is likely to be most
readily detectable in fully immunized children following
a booster dose, and unfortunately, much of the IPD bur-
den occurs prior to that time [19]. On the other hand,
certain vaccines with different conjugation methods and
carrier proteins have shown immunological cross-reac-
tivity against 19A, even following a primary dose series,
and could conceivably show greater protection against
disease. Whether they offer any protection against 19A
colonization remains to be determined. Accordingly, the
potential for clinically significant cross-protection
against 19A (and 6A) disease needs to be independently
considered for each new vaccine.
Methods
To systematically assess the clinical efficacy or effective-
ness of 19F-containing vaccines against 19A disease or
nasopharyngeal carriage, we searched for English-lan-
guage articles in the electronic databases PubMed, Cur-
rent contents, Scopus, and Embase from 1985 to 2008,
with the latest search conducted 15 May 2009. The key-
words used were “Sp n e u m o n i a e ““ 19A”, “19 A”, “pneu-
mococcal vaccine [MeSH Terms]”, “carriage”,
“colonization”, “invasive pneumococcal disease”,a n d
“acute otitis media.” In addition, we also consulted
recent reviews describing clinical trial results on naso-
pharyngeal carriage with 7vCRM for further references
and, where possible, searched abstracts from major
infectious diseases meetings in 2008 and the first half of
2009. For studies on disease, we only included reports
in which the authors themselves provided vaccine effi-
cacy or effectiveness calculations for 19A. The results
are summarized in tabular format in lieu of a formal
metanalysis, as the latter was considered inappropriate
due to the large variability in study design (efficacy or
effectiveness), vaccine dosing schedule, vaccines used,
and disease endpoints (IPD, AOM). Because there were
relatively few reports of vaccine effect on 19A nasophar-
yngeal carriage that included vaccine efficacy or effec-
tiveness calculations, we also included studies where we
could make those calculations based on case numbers.
￿ Summary
￿ Since the introduction of the 7-valent pneumococ-
cal conjugate vaccine (7vCRM), a rise in serotype
19A disease has been observed in the US and some
other countries with high antibiotic use, and this has
been taken to indicate that the 19F conjugate
included in the vaccine does not provide any cross-
protection against serotype 19A.
￿ However, clinical and post-licensure studies with
several 19F-containing vaccines, including 7vCRM,
consistently report modest clinical cross-protection
against 19A disease in fully immunized individuals.
￿ Consistent with this finding, 7vCRM elicits anti-
19A functional antibody responses that are detect-
able after the booster dose.
￿ New pneumococcal conjugate vaccines using dif-
ferent conjugation methods or carrier proteins
which elicit earlier and/or higher functional anti-19A
antibody responses could be more cross-protective
against 19A disease than 7vCRM.
Footnote
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